5β-Hydroxy-5β-cholestan-3-one | 19043-70-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 5β-Hydroxy-5β-cholestan-3-one
• 英文别名: 7-ketocholesterol；5-hydroxy-5β-cholestan-3-one；5-Hydroxy-5β-cholestan-3-on；5-β-hydroxy-cholestan-3-one；5β-Hydroxy-cholestan-3-on；5β-Hydroxycholestan-3-on；(5S,8S,9S,10R,13R,14S,17R)-5-hydroxy-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,4,6,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-one
• CAS: 19043-70-0
• 化学式: C₂₇H₄₆O₂
• 分子量: 402.661
• InChiKey: OPSNLRNZVIABPI-ZXOVMOMMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.5
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.96
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5β-Hydroxy-5β-cholestan-3-one 生成 4-胆甾烯-3-酮
  参考文献：
  名称：

  关于类固醇和性激素。155。约3α，5-二氧-邻前列腺素和两个差向异构的3,4-二氧-胆甾烷

  摘要：

  通过胆甾醇环氧化物的催化还原，可以以部分合成的方式制备3α，5-二氧-共前列腺素，其在不对称中心5的空间排列上对应于司他啡啶和相关糖苷配基的构型。

  DOI：

  10.1002/hlca.19480310647
• 作为产物：
  描述：

  5β-cholestanediol-(3α.5) 在 chromium(VI) oxide 、 溶剂黄146 作用下， 生成 5β-Hydroxy-5β-cholestan-3-one
  参考文献：
  名称：

  关于类固醇和性激素。155。约3α，5-二氧-邻前列腺素和两个差向异构的3,4-二氧-胆甾烷

  摘要：

  通过胆甾醇环氧化物的催化还原，可以以部分合成的方式制备3α，5-二氧-共前列腺素，其在不对称中心5的空间排列上对应于司他啡啶和相关糖苷配基的构型。

  DOI：

  10.1002/hlca.19480310647

文献信息

• Regio- and stereo-selective oxidation of steroids using 2,6-dichloropyridine N-oxide catalysed by ruthenium porphyrins
  作者：Tomoteru Shingaki、Keiko Miura、Tsunehiko Higuchi、Masaaki Hirobe、Tetsuo Nagano

  DOI：10.1039/a700096k

  日期：——

  Ruthenium porphyrins catalyse oxygen transfer from 2,6-dichloropyridine N-oxide to steroids with retention of configuration at the asymmetric centre, giving novel steroids.

  钌卟啉催化2,6-二氯吡啶 N-氧化物向甾体转移氧气，同时在不对称中心保持构型，生成新型甾体化合物。
• Use of derivatives of cholest-4-en-3-one as medicaments, pharmaceutical compositions containing same, novel derivatives and preparation method thereof
  申请人：Bordet Thierry

  公开号：US20060217358A1

  公开（公告）日：2006-09-28

  Compound of formula I where X=O or ═N—OH group, R represents a group chosen from A=hydrogen or together with B a carbon-carbon bond, B=hydrogen, hydroxy or together with A a carbon-carbon bond, C, D, E, F=hydrogen or together with D a carbon-carbon bond, or the one of its addition salts with pharmaceutically acceptable acids, with the exception of a few compounds, as a medicament, use in particular as neuroprotectors, novel compounds of formula I and pharmaceutical compositions.

  化合物I的化学式如下，其中X可以是O或═N—OH基团，R代表从以下组中选择的一种：A=氢或与B一起形成碳-碳键，B=氢、羟基或与A一起形成碳-碳键，C、D、E、F=氢或与D一起形成碳-碳键，或其与药学上可接受的酸的一种或多种加成盐，除了少数化合物外，作为药物，特别是作为神经保护剂，化合物I的新型化合物和制药组合物。
• USE AS MEDICAMENTS OF DERIVATIVES OF CHOLEST-4-EN-3-ONE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, NOVEL DERIVATIVES AND THEIR PREPARATION PROCESS
  申请人：BORDET Thierry

  公开号：US20100216752A1

  公开（公告）日：2010-08-26

  A method for providing neuroprotection to a patient in need of neuroprotection, comprising administering a neuroprotective-effective amount of a compound of formula I in which X is an oxygen atom or an ═N—OH group, R is selected from the group consisting of A is a hydrogen atom or together with B a carbon-carbon bond, B is a hydrogen atom, a hydroxy group or together with A a carbon-carbon bond, C is a hydrogen atom or together with D a carbon-carbon bond, D is a hydrogen atom or together with C a carbon-carbon bond, E is a hydrogen atom or together with F a carbon-carbon bond, F is a hydrogen atom or together with E a carbon-carbon bond, or an addition salt with a pharmaceutically acceptable acid.

  一种用于向需要神经保护的患者提供神经保护的方法，包括给予化合物I的神经保护有效量，其中X是氧原子或═N—OH基团，R选自以下组合：A是氢原子，或者与B一起形成碳-碳键，B是氢原子、羟基或者与A一起形成碳-碳键，C是氢原子，或者与D一起形成碳-碳键，D是氢原子，或者与C一起形成碳-碳键，E是氢原子，或者与F一起形成碳-碳键，F是氢原子，或者与E一起形成碳-碳键，或者与药学上可接受的酸形成加成盐。
• METHOD FOR PROVIDING NEUROPROTECTION
  申请人：Bordet Thierry

  公开号：US20120309721A1

  公开（公告）日：2012-12-06

  A method for providing neuroprotection to a patient in need of neuroprotection, comprising administering a neuroprotective-effective amount of a compound of formula I in which X is an oxygen atom or an =N—OH group, R is selected from the group consisting of A is a hydrogen atom or together with B a carbon-carbon bond, B is a hydrogen atom, a hydroxy group or together with A a carbon-carbon bond, C is a hydrogen atom or together with D a carbon-carbon bond, D is a hydrogen atom or together with C a carbon-carbon bond, E is a hydrogen atom or together with F a carbon-carbon bond, F is a hydrogen atom or together with E a carbon-carbon bond, or an addition salt with a pharmaceutically acceptable acid.

  一种为需要神经保护的患者提供神经保护的方法，包括给予化合物I的神经保护有效剂量，其中X是氧原子或=N-OH基团，R从以下组中选择：A是氢原子或与B一起形成碳-碳键，B是氢原子、羟基或与A一起形成碳-碳键，C是氢原子或与D一起形成碳-碳键，D是氢原子或与C一起形成碳-碳键，E是氢原子或与F一起形成碳-碳键，F是氢原子或与E一起形成碳-碳键，或与药学上可接受的酸形成加成盐。
• METHOD FOR PROVIDING NEUROPROTECTION FROM SPINAL MUSCULAR ATROPHY
  申请人：BORDET Thierry

  公开号：US20120316141A1

  公开（公告）日：2012-12-13

  A method for providing neuroprotection to a patient in need of neuroprotection, comprising administering a neuroprotective-effective amount of a compound of formula I in which X is an oxygen atom or an ═N—OH group, R is selected from the group consisting of A is a hydrogen atom or together with B a carbon-carbon bond, B is a hydrogen atom, a hydroxy group or together with A a carbon-carbon bond, C is a hydrogen atom or together with D a carbon-carbon bond, D is a hydrogen atom or together with C a carbon-carbon bond, E is a hydrogen atom or together with F a carbon-carbon bond, F is a hydrogen atom or together with E a carbon-carbon bond, or an addition salt with a pharmaceutically acceptable acid.

  一种为需要神经保护的患者提供神经保护的方法，包括给予化学式I中X为氧原子或═N—OH基团，R选自以下组合的神经保护有效量的化合物：A为氢原子或与B一起形成碳-碳键，B为氢原子、羟基或与A一起形成碳-碳键，C为氢原子或与D一起形成碳-碳键，D为氢原子或与C一起形成碳-碳键，E为氢原子或与F一起形成碳-碳键，F为氢原子或与E一起形成碳-碳键，或与药用可接受酸形成加合物的盐。